KYBELLA® (deoxycholic acid) injection 10 mg/mL Puts "Profiles in Focus" With Expert Panel And New Direct-To-Consumer Campaign

• On your feet: Sitting for a photo can add weight (especially if you slouch). I prefer my clients to stand, which just naturally elongates the body."
• Find the right chin angle: "In my studio, the positioning of a subject's chin is one of the first things I discuss before we shoot. The best way to ensure a strong chin angle is to face the camera and bring your forehead toward the camera and slightly down. Once your chin is in the right position, imagine there's a hook attached to the crown of your head that's pulling you toward the ceiling. Your goal is to elongate the neck and tighten the skin around your jawline so the light can wrap around it more sharply."
• Don't forget to squinch: "Squinching" is a technique I made up for my clients to help them look more attractive and approachable. To "squinch," bring your lower eyelids up slightly toward your pupils. Practice in a mirror and you'll notice a subtle but impactful difference."
• Hold a sub: "To slim your upper arms and shoulders, position yourself as if you are holding a large sub sandwich with your elbows tucked into your sides. Then widen your hands as if holding a 6 foot-long sub, with your elbows still tucked. The difference is incredible."
• The best background: "My headshots are typically done on a white background, which is clean and simple. I also prefer a close horizontal crop. The open space it creates around a subject can be very impactful and creates what I call "lookability," which is the ability of an image to get attention."
• The right crop: "After you have an image you like, it's time to crop it effectively. I like to zoom in and crop a little off the top of a subject's head. This puts the eyes above the centerline of the image and calls attention to the chin line and shoulders as well."

But it's not just about looking great in that selfie. Having the wrong social media profile picture can also be bad business. "Social media has given everyone the opportunity to be their own brand and allow potential employers to see who you are beyond your résumé, cover letter, or interview," says Maggie Mistal, career counselor and host of the podcast "Make a Living with Maggie. "And of course your photo is an important component of your social profile."

To create or select a profile photo that may help get a hiring manager's attention, Career Counselor Maggie Mistal has the following tips:

• Go it alone: "Make sure your image is a professional-looking headshot of you alone. Avoid cropping other people out of photos, which never looks professional, and avoid distracting backgrounds like tourist landmarks."
• Say cheese: "Look at the camera and smile. Your image and facial expression should draw people in for a closer look.  You want people to be interested in who you are and excited about getting to know you better."
• Be consistent: "Once you have a winning image use it across all your channels – not just LinkedIn. Don't assume because you use Facebook to connect with friends and family a prospective employer won't look there."
• Beyond the profile photo: "Remove any photos that depict you in an unflattering way (and I don't mean physically), but be sure to share photos that give employers a positive look at your life and interests outside of work. For example, if you run marathons or volunteer in the community, make sure to share those photos. 

To start the conversation and motivate people to learn more about KYBELLA^®, the brand launched a new direct-to-consumer campaign, designed to resonate with men and women who have a double chin and introduce them to this minimally invasive injectable treatment for moderate to severe fat under the chin. The national TV campaign emphasizes that double chin isn't just caused by aging – it can also be genetic.  And with KYBELLA^® you can do something about that double chin you "inherited."

To learn more about submental fullness and the Live Chin Up Campaign, visit www.LiveChinUp.com. To learn more about KYBELLA^® and find a physician in your area visit www.MyKybella.com

KYBELLA^® Approved Use and Important Safety Information

What is KYBELLA^®?
KYBELLA^® is a prescription medicine used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called "double chin."

It is not known if KYBELLA^® is safe and effective for use outside of the submental area or in children under the age of 18.

Who should not receive KYBELLA^®?
You should not receive KYBELLA^® if you have an infection in the treatment area.

Before receiving KYBELLA^®, tell your healthcare provider about all of your medical conditions, including if you: Have had or plan to have surgery on your face, neck, or chin; have had cosmetic treatments on your face, neck, or chin; have had or have medical conditions in or near the neck area; have had or have trouble swallowing; have bleeding problems; are pregnant or plan to become pregnant (it is not known if KYBELLA^® will harm your unborn baby); are breastfeeding or plan to breastfeed (it is not known if KYBELLA^® passes into your breast milk; talk to your healthcare provider about the best way to feed your baby if you receive KYBELLA^®).

Tell your healthcare provider about all the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take a medicine that prevents the clotting of your blood (antiplatelet or anticoagulant medicine).

What are the possible side effects of KYBELLA^®?

KYBELLA^® can cause serious side effects, including nerve injury in the jaw (which can cause an uneven smile or facial muscle weakness), or trouble swallowing.

The most common side effects of KYBELLA^® include: swelling, bruising, pain, numbness, redness, and areas of hardness in the treatment area.

These are not all of the possible side effects of KYBELLA^®. Call your healthcare provider for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/MedWatch or call 1-800-FDA-1088.

Please talk to your healthcare provider or visit www.mykybella.com for full Prescribing Information.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care.  This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life.  Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 (such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

References
^1. American Society for Dermatologic Surgery 2015 Consumer Survey on Cosmetic Dermatologic Procedures, 2015. "How Bothered Are You By Excess Fat Under The Chin/Neck?"
^2. Schlessinger J, Weiss SR, Jewell M, Narurkar V, Weinkle S, Gold MH, Bazerkanian E. Perceptions and Practices in Submental Fat Treatment: A Survey of Physicians and Patients. SKINmed Dermatology for the Clinician. 2013; 11(1):27-31.
^3. KYBELLA^® Prescribing Information, 2015.

© 2016 Allergan. All rights reserved. All trademarks are the property of their respective owners.

KYB102113  09/16

CONTACTS:                                     
Investors:
Lisa DeFrancesco                                                                                         
(862) 261-7152

Media:
Mark Marmur
(862) 261-7558
Ember Garrett
(714) 246-3525

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kybella-deoxycholic-acid-injection-10-mgml-puts-profiles-in-focus-with-expert-panel-and-new-direct-to-consumer-campaign-300350408.html

SOURCE Allergan plc